By the Top Tier Newswire AI Desk · October 9, 2026 at 10:13 AM ET · reviewed against 3 wire stories
IMMUNITYBIO INC (IBRX) is up +7.37% in the latest session. Our newswire has captured 3 stories on IBRX across 3 sources in the last 36 hours, with AI sentiment reading mixed (avg 56/100).
ImmunityBio (IBRX) shares rose 7.37% to $10.64, driven by the announcement that founder and Executive Chairman Dr. Patrick Soon-Shiong will participate in a virtual fireside chat at the Piper Sandler Virtual Oncology Symposium on October 16, 2026. The company stated it plans to discuss the progress of its lead drug, ANKTIVA, during the event. This catalyst followed recent regulatory approvals and strong quarterly results, contributing to a significant upward move in the stock price.
What Happened
ImmunityBio confirmed that Dr. Soon-Shiong will join the Piper Sandler Virtual Oncology Symposium to highlight the development of ANKTIVA. The company emphasized that the initiative aligns with its "Immunotherapy 2.0" vision, which combines immune treatments, diagnostics, and monitoring to help prevent cancer recurrence. This announcement comes shortly after the drug received approval in the United Arab Emirates for non-small cell lung cancer, a decision based on the QUILT-3.055 trial which showed a 14.6-month median overall survival in checkpoint-refractory patients. Additionally, the company recently achieved the world's broadest bladder cancer approval for ANKTIVA.
In its most recent quarterly report, ImmunityBio reported adjusted earnings per share of $(0.08), which beat the estimate of $(0.09). Sales came in at $51.240 million, exceeding the $49.700 million estimate. These financial results, combined with the upcoming symposium appearance, have fueled renewed interest in the stock.
What The Data Shows
The stock opened at $9.96 and reached a session high of $10.67 at 10:10 AM ET before settling near $10.55. Volume stood at 3.1 million shares, which is 0.3 times the 3-month daily average. The company has a market capitalization of $10.3 billion and remains unprofitable with a trailing twelve-month EPS of -0.99. However, revenue has grown 192.9% over the trailing twelve months. The 52-week range spans from $1.95 to $12.43. Over the last eight sessions, the stock has climbed 12.2% from $8.84 to $9.91. Recent insider activity shows two sales totaling $1.1 million in the last 90 days, with no purchases recorded.
What To Watch
Investors will look to the October 16, 2026, fireside chat for further details on ANKTIVA's clinical progress and the company's broader immunotherapy strategy.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.